Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme

Journal of Neuro-Oncology

Volumn 108, Issue 1, 2012, Pages 173-177

  Roldán Urgoiti, Gloria B ^a   Singh, Amitabh D ^a   Easaw, Jacob C ^a  

^a TOM BAKER CANCER CENTRE   (Canada)

Author keywords

Cohort study; Extended chemotherapy; Glioblastoma multiforme; Radiation therapy; Survival; Temozolomide

Indexed keywords

ETOPOSIDE; LOMUSTINE; TEMOZOLOMIDE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER REGISTRY; CANCER SURVIVAL; DISEASE ASSOCIATION; DRUG TOXICITY; EXTENDED ADJUVANT CHEMOTHERAPY; FEMALE; GLIOBLASTOMA; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PATIENT CODING; POPULATION RESEARCH; PROGRESSION FREE SURVIVAL; SURVIVAL PREDICTION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DACARBAZINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84863415618     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-012-0826-3     Document Type: Article

References (14)

1. H Ohgaki P Kleihues 2005 Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas J Neuropathol Exp Neurol 64 479 489 15977639 1:CAS:528:DC%2BD2MXlvVSgsbg%3D (Pubitemid 40781150)
2. R Stupp WP Mason MJ van den Bent, et al. 2005 Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 987 996 15758009 10.1056/NEJMoa043330 1:CAS:528:DC%2BD2MXit1Wksbk%3D (Pubitemid 40349501)
3. R Stupp ME Hegi WP Mason, et al. 2009 Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5 year analysis of the EORTC-NCIC trial Lancet Oncol 10 459 466 19269895 10.1016/S1470-2045(09)70025-7 1:CAS:528:DC%2BD1MXlsVKhs74%3D
4. ES Newlands MF Stevens SR Wedge RT Wheelhouse C Brock 1997 Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials Cancer Treat Rev 23 35 61 9189180 10.1016/S0305-7372(97)90019-0 1:CAS:528:DyaK2sXktFOrt7w%3D (Pubitemid 27273454)
5. P Hau D Koch T Hundsberger, et al. 2007 Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma Neurology 68 688 690 17325277 10.1212/01.wnl.0000255937.27012.ee 1:CAS:528: DC%2BD2sXhvFWrs7c%3D (Pubitemid 46667817)
6. WP Mason RD Maestro D Eisenstat, et al. 2007 Canadian recommendations for the treatment of glioblastoma multiforme Curr Oncol 14 110 117 17593983 10.3747/co.2007.119 1:STN:280:DC%2BD2sznsl2jtQ%3D%3D (Pubitemid 47204238)
7. DR Macdonald TL Cascino SC Schold Jr JG Cairncross 1990 Response criteria for phase II studies of supratentorial malignant glioma J Clin Oncol 8 1277 1280 2358840 1:STN:280:DyaK3c3ptlyitQ%3D%3D (Pubitemid 20195640)
8. ME Hegi AC Diserens T Gorlia, et al. 2005 MGMT gene silencing and benefit from temozolomide in glioblastoma N Engl J Med 352 997 1003 15758010 10.1056/NEJMoa043331 1:CAS:528:DC%2BD2MXit1Wktro%3D (Pubitemid 40349502)
9. T Andre C Louvet F Maindrault-Goebel, et al. 1999 CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR Eur J Cancer 35 1343 1347 10658525 10.1016/S0959-8049(99)00150-1 1:CAS:528:DyaK1MXls1Wjsbs%3D (Pubitemid 29397434)
10. AA Brandes E Franceschi A Tosoni, et al. 2008 MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients J Clin Oncol 26 2192 2197 18445844 10.1200/JCO.2007.14.8163
11. GB Roldan JN Scott JB McIntyre, et al. 2009 Population-based study of pseudoprogression after chemoradiotherapy in GBM Can J Neurol Sci 36 617 622 19831132
12. P Sanghera J Perry A Sahgal, et al. 2010 Pseudoprogression following chemoradiotherapy for glioblastoma multiforme Can J Neurol Sci 37 36 42 20169771
13. W Taal D Brandsma HG de Bruin, et al. 2008 Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide Cancer 113 405 410 18484594 10.1002/cncr.23562 1:CAS:528:DC%2BD1cXpt1Orsbs%3D
14. Gilbert MR, Wang M, Aldape KD, et al. (2011) RTOG 0525: a randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM). J Clin Oncol 29:2006. (Abstract)